OncoSec Medical Names Adil Daud, M.D. as Chief Clinical Strategist
April 23 2014 - 6:03AM
Business Wire
Company Appoints Nationally Renowned Expert in
Targeted Therapies for Melanoma to Clinical Leadership Role
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its
ImmunoPulse DNA-based immunotherapy to treat solid tumors, has
named Adil Daud, M.D. as Chief Clinical Strategist.
Dr. Daud is a longstanding member of OncoSec’s Melanoma Advisory
Board and serves as Principal Investigator for OncoSec’s Phase 2
melanoma study. He is a clinical professor of hematology/oncology
at University of California, San Francisco (UCSF), and Director of
Melanoma Clinical Research at the UCSF Helen Diller Family
Comprehensive Cancer Center. Dr. Daud is a nationally recognized
expert in early-phase drug development in skin cancer and solid
tumors, and has co-authored more than 60 scientific publications.
Prior to joining UCSF in 2008, Dr. Daud served at Memorial
Sloan-Kettering Cancer Center in New York and H. Lee Moffitt Cancer
Center in Florida. He has been the recipient of numerous awards,
including the American Society for Clinical Oncology’s Young
Investigator award and Castle Connolly’s Best Doctors in America
award.
Dr. Daud said, “I am both honored and excited to take on this
expanded role as Chief Clinical Strategist for OncoSec Medical. I
believe this is a watershed moment in oncology, and that
intralesional therapies like those being advanced by the OncoSec
team have the potential to provide serious benefit to many patients
around the globe.”
“Dr. Daud is a pioneer in the field of gene-electro therapy,”
said Punit Dhillon, President and CEO. “His Phase I study
investigating the use of in-vivo electroporation to deliver plasmid
DNA laid the groundwork for OncoSec’s formation, and his efforts
have proved integral to the company’s development. Adil’s work
continues to support his status as a key opinion leader in
intralesional immunotherapies.”
As Chief Clinical Strategist, Dr. Daud will take on an expanded
clinical leadership role. Among his central duties will be to
advise on protocol and development, liaise with key stakeholders
and represent the company at conferences and other important
events.
Said Robert Pierce, M.D., Chief Medical Officer, “Working with
Adil has been a pleasure. Together, our team looks forward to
driving the clinical development of our pIL-12-based ImmunoPulse in
melanoma and other solid tumor indications, as well as delivering
new drug candidate INDs.”
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing
its ImmunoPulse immunotherapy to treat solid tumors. OncoSec
Medical's core technology leverages a proprietary electroporation
platform to enhance the local delivery and uptake of
IL-12 and other DNA-based immune-modulating agents. Clinical
studies of ImmunoPulse have demonstrated an acceptable safety
profile and preliminary evidence of anti-tumor activity in the
treatment of various skin cancers, as well as the potential to
initiate a systemic immune response without the systemic toxicities
associated with other treatments. OncoSec's clinical programs
currently include three Phase 2 trials targeting metastatic
melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma
(http://clinicaltrials.gov/ct2/results?term=oncosec&Search=Search).
As the company continues to evaluate ImmunoPulse in these
indications, it is also investigating additional indications and
combination therapeutic approaches. For more information, please
visit www.oncosec.com.
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this release that are not historical facts
may be considered such “forward-looking statements.”
Forward-looking statements are based on management’s current
preliminary expectations and are subject to risks and
uncertainties, which may cause our results to differ materially and
adversely from the statements contained herein. Some of the
potential risks and uncertainties that could cause actual results
to differ from those predicted include our ability to raise
additional funding, our ability to acquire, develop or
commercialize new products, uncertainties inherent in pre-clinical
studies and clinical trials, unexpected new data, safety and
technical issues, competition, and market conditions. These and
additional risks and uncertainties are more fully described in
OncoSec Medical’s filings with the Securities and Exchange
Commission. Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. OncoSec
Medical disclaims any obligation to update any forward-looking
statements to reflect new information, events or circumstances
after the date they are made, or to reflect the occurrence of
unanticipated events.
OncoSec Medical Inc.Investor Relations:Veronica Vallejo,
CFO855-662-6732investors@oncosec.com
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Mar 2024 to Apr 2024
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Apr 2023 to Apr 2024